An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
Latest Information Update: 30 Sep 2022
At a glance
- Drugs CKD-388 (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 26 Sep 2022 Status changed from not yet recruiting to completed.
- 20 Jan 2022 New trial record